Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma

BACKGROUND: TP300, a recently developed synthetic camptothecin analogue, is a highly selective topoisomerase I inhibitor. A phase I study showed good safety and tolerability. As camptothecins have proven active in oesophago-gastric adenocarcinomas, in this phase II study we assessed the efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales: Propper, David, Jones, Keith, Anthoney, D. Alan, Mansoor, Wasat, Ford, Daniel, Eatock, Martin, Agarwal, Roshan, Inatani, Michiyasu, Saito, Tomohisa, Abe, Masaichi, Evans, T. R. Jeffry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5057500/
https://www.ncbi.nlm.nih.gov/pubmed/27724887
http://dx.doi.org/10.1186/s12885-016-2828-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5057500/
https://www.ncbi.nlm.nih.gov/pubmed/27724887
http://dx.doi.org/10.1186/s12885-016-2828-6

Ejemplares similares